Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NeuroBo Pharmaceuticals Inc NRBO

Healthcare Biotechnology
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NRBO)

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire 7 days ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

PR Newswire April 30, 2024

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

PR Newswire April 17, 2024

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

PR Newswire April 1, 2024

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

PR Newswire March 28, 2024

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

PR Newswire March 13, 2024

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

PR Newswire March 4, 2024

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

PR Newswire February 29, 2024

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

PR Newswire February 12, 2024
View More News ››

Opinion & Analysis (NDAQ:NRBO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NRBO)

NRBO.....low vol on NR this a.m

On watch
Iseneschal - March 13, 2024

Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations

BREAKING NEWS: $NRBO Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations | BenzingaU.S. stocks traded higher midway through...
whytestocks - February 1, 2024

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a

News; $NRBO NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of...
whytestocks - February 1, 2024

NRBO .... Heads up ; )

A break of $1.65 could be meaningful
Iseneschal - November 23, 2022

NRBO...... On watch

Nice volume .....it just needs some Price action Coin toss
Iseneschal - November 23, 2022

NRBO ..... BTFD anyone ?

Or am I the only one with the cajoles ???  LMFAO
Iseneschal - November 10, 2022
View more Bullboard ››

Vertiqal Studios Corp.

Vertiqal Studios Corp.

Vertiqal Studios is a leading global digital media entertainment, production, and distribution company redefining the ...
View More »